Skip to main content
Critical Care logoLink to Critical Care
. 2017 Jan 8;21:5. doi: 10.1186/s13054-016-1585-x

Normal saline versus heparin for patency of central venous catheters in adult patients - a systematic review and meta-analysis

Lei Zhong 1, Hai-Li Wang 2, Bo Xu 1, Yao Yuan 3, Xin Wang 4, Ying-ying Zhang 1, Li Ji 1, Zi-mu Pan 1, Zhan-Sheng Hu 1,
PMCID: PMC5219914  PMID: 28063456

Abstract

Background

Heparin saline (HS) is theoretically superior to normal saline (NS) for maintaining the patency of central venous catheters (CVCs), but the comparative efficacy of them remains controversial. The aim of this systematic review and meta-analysis was to assess the efficacy of NS versus HS in the maintenance of the patency of CVCs in adult patients.

Methods

We searched PubMed, Embase and the Cochrane library databases. Randomized controlled trials (RCTs) evaluating the use of NS vs. HS to maintain the permeability of CVCs among adult patients were included in our meta-analysis. References of relevant papers were reviewed manually. No language restriction was applied. Non-human studies were excluded. Pooled relative risk (RR) was calculated using a Mantel-Haenszel random-effects model. We also performed subgroup analysis examining the effect of the duration of catheter placement on the outcome. All statistical tests were two-sided using a significance level of 0.05.

Results

Ten RCTs involving 7875 subjects (with analysis at patient, catheter, lumen and line access level) were included in this meta-analysis. Whether in terms of pooled or local analysis (RR with 95% confidence interval spans 1), NS can be equally, if not more effective, in keeping the CVCs open. Of studies reporting secondary outcomes (maneuver needed, heparin-induced thrombocytopenia, haemorrhage, central venous thrombosis and catheter-related bloodstream infection), heparinised saline was shown not to be superior to non-heparinised solution. Subgroup analysis in patients with short vs long term CVC placement was consistent with the main outcome partly and in particular for maintenance of catheter patency in patients with a long-term placement i.e. >30 days, the RR was 0.97 (n = 6589; 95% CI = 0.76 to 1.23; P = 0.796). However, for patients in whom the catheter was in place for <30 days, the RR was 1.52 (n = 1286; 95% CI = 1.02 to 2.27; P = 0.041).

Conclusions

Based on the results of this meta-analysis, HS is not superior to NS in reducing CVCs occlusion. But in the short term, the use of HS is slightly superior to NS for flushing catheters from a statistical point of view.

Electronic supplementary material

The online version of this article (doi:10.1186/s13054-016-1585-x) contains supplementary material, which is available to authorized users.

Keywords: Normal saline, Heparin, Central venous catheters, Occlusion

Background

Central venous catheters (CVCs) are widely utilized in clinical practice, especially in intensive care units (ICUs) [1]. These devices are inserted so as to enable the administration of fluids, blood products, medications, parenteral nutrition, and for the performance of dialysis and central venous pressure monitoring [2, 3]. Currently, there are four types of CVCs: non-tunneled, tunneled, peripherally nserted central catheters (PICCs) and totally implantable venous access devices (TIVADs) [4].

These central lines will remain in place for days or even weeks each time [5]. Prolonged use may result in catheter occlusion, which may give rise to a requirement for the catheter to be treated, removed or replaced. Inserting a new central line creates latent threats, which could lead to disrupted treatment, increasing morbidity, and greater spending on health care [5]. Generally, catheter obstruction can be defined as partial occlusion (inability to aspirate blood but ability to flush freely) or complete occlusion (inability to flush freely and withdraw blood). It is estimated that the occlusion rate is between 0% and 33% when using heparin saline (HS) solution [6, 7]. Factors leading to catheter obstruction can be generally classified into three categories: mechanical causes, drug/mineral precipitates and clot formation, which is the most common reason overall [8]. To avoid the risk of catheter occlusion, thrombosis and catheter-related bloodstream infection (CRBSI), proper catheter flushing and locking are always considered to be the primary intervention because of the effect of reducing blood reflux into the lumen [8, 9].

Unfractionated heparin is well-known for its anticoagulant activity. Thus, heparin is widely used to maintain the patency of CVCs [10]. Nonetheless, the efficacy of this practice has not been definitively shown. Moreover, the use of heparinised saline is associated with potential risks such as coagulation disorders, hypersensitivity reactions and heparin-induced thrombocytopenia (HIT) [11, 12]. Researchers have been looking for a safe alternative to heparin, such as isotonic saline, vitamin C, lepirudin, sodium citrate or polygeline, to improve this situation [1316]. Especially important, if there was a suitable replacement for HS, that would be beneficial, especially for patients with contraindications to using HS.

There have been numerous publications in this field over the last few years, including a guideline [17], several trials [2, 10] and several reviews [5, 9], including a Cochrane Review [18]. Most of these studies indicate that normal saline (NS) is safe and efficacious in preventing catheter occlusion in adult populations with CVCs. The recent guideline concluded that routine flushing with NS is recommended. However, the Cochrane review showed that there is no clear evidence to indicate whether NS flushing is superior to flushing with HS solution.

CVC occlusion is a fairly common problem, but differences in methods of prophylaxis, diagnosis and treatment practices related to catheter lumen obstruction vary, perhaps as a result of a lack of appropriate clinical guidelines [19]. An evidence-based, standardized flushing protocol is required for CVCs in adults. We conducted a systematic review and meta-analysis to evaluate the clinical efficacy (benefits and harms) of NS flushes and HS flushes for prevention of CVC lumen occlusion in adult patients.

Methods

Our systematic review and meta-analysis was conducted according to preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines (Additional file 1) [20]. The PICO framework was applied to define the clinical question clearly (Additional file 2). The primary outcome was catheter occlusion. Secondary outcomes included: maneuver needed (patients who required catheter manipulation to maintain the patency of the lumen), HIT, haemorrhage, central venous thrombosis and CRBSI.

Search strategy and selection criteria

We systematically searched PubMed, Embase and the Cochrane library databases from the inception to 28 September 2016, using the following terms: “Sodium Chloride”, “Saline Solution, Hypertonic”, “NaCl”, “Heparin”, “Catheterization, Central Venous”, “Randomized Controlled Trial”, etc. (Additional file 3). There was no restriction on language. We also reviewed bibliographies in the retrieved articles to identify additional relevant studies. Only clinical randomized controlled trials (RCTs) of NS flushing vs flushing with HS solution in adults were included. Exclusion criteria were (1) age <18 years, and (2) case reports, letters, reviews, case-control studies and cohort studies, or non-human studies.

Data extraction

Data were independently extracted by three reviewers (ZL, YY and WX). The following information was abstracted from the included studies: Study ID, mean age (years), country origin, number of subjects (NS/HS), female (%), centre, ICUs, disease types, follow up (days), heparin concentration (IU/ml) and heparin volume (ml). Disagreements were resolved by consensus.

Assessment of study quality

The quality of the individual studies was assessed based on the Cochrane handbook for systemic reviews of interventions [21].

Assessment of risk of bias

We performed sensitivity analysis to assess the influence of a single study on the pooled effects. Simultaneously, we used a funnel plot for assessment of publication bias [22].

Statistical analysis

The pooled effects were analyzed by relative risk (RR) with 95% confidence interval (CI) for dichotomous outcomes. Statistical heterogeneity among trials was quantitatively assessed with the X2 test, P values and the I 2 statistics [23]. We pooled data using Mantel-Haenszel random-effects models, which are more conservative in their estimations [24].

During the search process, there were four different kinds of subjects for analysis: patients (six studies), catheters (two studies), lumens (one study; multilumen CVCs) and line access (one study; flushing central lines before and after each use). Given this, our meta-analysis was to be analysed separately on the basis of definite features of units.

In light of the Ge and Schallom study [2, 25], the duration of catheter placement is classified as short-term (less than 3–4 wks) and long-term (months to years). Simultaneously, subgroup analysis based on the length of indwelling time was carried out to characterize possible sources of heterogeneity(e.g. <30 and >30 days). All statistical tests were two-sided using an α level of 0.05. This meta-analysis was conducted using Stata 12.0 software (StataCorp, College Station, TX, USA) and Review Manager Version 5.3.5 (available from http://tech.cochrane.org/revman/download).

Results

Search results and study characteristics

The chart for the selection process and detailed information is given in Fig. 1. The literature search yielded 542 publications up to 28 September, 2016. We excluded 532 articles during the screening process. Thus, a total of 10 studies were eligible according to the inclusion criteria. The 10 studies were from Germany [13] (n = 1), Spain [6] (n = 1), Belgium [26] (n = 1), Italy [27] (n = 1), Japan [28] (n = 1), Iran [29, 30] (n = 2) and the USA [2, 31, 32] (n = 3). As a result, the 10 trials, including four ICU and six non-ICU studies, were reported in the years 2002–2015 and the average duration of follow up ranged from 1 to 400 days. The average age of the patients ranged from 51.6 to 68.43 years, and the proportion of female patients ranged from 31% to 65.34%. The different concentrations of heparin recorded in the existing publications ranged from 10 IU/mL to 5000 IU/ml.

Fig. 1.

Fig. 1

Flow chart of article selection procedure

In the Lyons trial [31], a comparison of 0.9% NaCl with two different concentrations of heparin (10 and 100U/ml) was presented. Consequently, we divided the data into two sets and performed statistical analysis. Ultimately, our study yielded 11 datasets from 10 RCTs. The baseline characteristics of the 10 eligible RCTs are shown in Table 1.

Table 1.

Main characteristics of the included studies

Study ID Mean age (years) Country origin Subjects, number (NS/HS) Female (%) Centre ICUs Disease types Follow up (days) Heparin concentration (IU/ml) Heparin volume (ml)
Rabe 2002 [13] 59.25 Germany 33/33 63.64 S Y Multi-disease 20 5000 0.5
Kaneko 2004 [28] 68.43 Japan 26/22 50.00 S N Nephropathy 48 1000 2
Pumarola 2007 [6] 52.27 Spain 57/38 31.60 M Y Multi-disease 3 100 5
Bowers 2008 [32] 54.36 USA 50/52 50.00 S N Multi-disease 10.3 100 3
Schallom 2012 [2] 58.69 USA 150/145 48.81 S Y Multi-disease 14 10 3
Goossens 2013 [26] 55.81 Belgium 404/398 65.34 S N Cancer patients 180 100 3
Beigi 2014 [29] 63.1 Iran 49/47 45.83 S N Multi-disease 1 100
Lyons 2014 [31] 52 USA 28/30 40 H N Multi-disease 23 10 5
Lyons 2014 [31] 52 USA 28/32 40 H N Multi-disease 23 100 3
Molin 2015 [27] 62.69 Italy 203/212 53.49 M N Cancer patients 400 50 5
Ziyaeifard 2015 [30] 51.6 Iran 50/50 31.00 S Y Cardiac surgery 3 10 5

S single-centre study, M multi-centre study, H home care patient, Y yes, N no

Assessment of study quality

The risk of bias in the included studies is summarized in Fig. 2. It indicated that two papers had high risk of bias as they failed to obtain the expected sample size [6, 27], and one study was subject to detection bias, as the outcome measurement could have been influenced by lack of blinding [27].

Fig. 2.

Fig. 2

Risk of bias assessment. a Risks of bias graph. b Risks of bias summary

Assessment of reporting biases

We conducted sensitivity analysis, which suggested that the Goossens [26] study was the main source of statistical heterogeneity in our meta-analysis. However, we found it complied completely with the inclusion standards. Examination of the funnel plot suggests that there was also publication bias (Fig. 3).

Fig. 3.

Fig. 3

Funnel plot was generally asymmetrical. The black dots and dotted line indicate individual studies and 95% confidence intervals, respectively

The forest plot data prepared using Mantel-Haenszel random-effects models is summarized in Table 2.

Table 2.

The summary results of all 10 studies

Result Primary outcomes Secondary outcomes Subgroup analysis
Pooled effect Catheter Line access Lumen Patient Maneuver needed HIT Haemorrhage CVT CRBSI Short Long
RR 1.21 3.00 0.92 1.66 1.33 1.24 1.33 0.75 0.81 0.84 1.52 0.97
95% CI lower-bound 0.91 0.89 0.71 0.85 0.86 0.71 0.09 0.32 0.50 0.11 1.02 0.76
95% CI upper-bound 1.61 10.10 1.19 3.24 2.07 2.16 18.54 1.74 1.31 6.71 2.27 1.23
P value 0.186 0.076 0.524 0.141 0.205 0.457 0.834 0.501 0.381 0.871 0.041 0.796

HIT heparin-induced thrombocytopenia, CVT central venous thrombosis, CRBSI catheter-related bloodstream infection, RR relative risk, CI confidence interval

Synthesis of primary outcome

Pooled analysis was performed using a Mantel-Haenszel random-effects model and reported as RR with 95% CI (n = 7875; RR, 1.21; 95% CI = 0.91 to 1.61; P = 0.186), with a low heterogeneity among these studies (X 2 = 8.39, P = 0.299; I 2 = 16.6%).

From the catheter (n = 161; RR, 3.00; 95% CI = 0.89 to 10.10; P = 0.076), line access (n = 6126; RR, 0.92; 95% CI = 0.71 to 1.19; P = 0.524), lumen (n = 709; RR, 1.66; 95% CI = 0.85 to 3.24; P = 0.141) and patient (n = 879; RR, 1.33; 95% CI = 0.86 to 2.07; P = 0.205), HS is not superior to NS in preventing catheter occlusion (Fig. 4).

Fig. 4.

Fig. 4

Forest plot of association between use of normal saline (NS) vs heparin saline (HS) and the incidence of catheter occlusion. RR relative risk, CI confidence interval, NS normal saline, HS heparin saline

Secondary outcomes

For maneuver needed (n = 196; RR, 1.24; 95% CI = 0.71 to 2.16; P = 0.457), heparin-induced thrombocytopenia (n = 1263; RR, 1.33; 95% CI = 0.09 to 18.54; P = 0.834), haemorrhage (n = 439; RR, 0.75; 95% CI = 0.32 to 1.74; P = 0.501), central venous thrombosis (n = 1512; RR, 0.81; 95% CI = 0.50 to 1.31; P = 0.381) and catheter-related bloodstream infection (n = 1630; RR, 0.84; 95% CI = 0.11 to 6.71; P = 0.871), flushing CVCs with NS was as effective as HS (Fig. 5).

Fig. 5.

Fig. 5

Forest plot of association between use of NS vs HS and the incidence of complications. RR relative risk, CI confidence interval, NS normal saline, HS heparin saline

The results of subgroup analysis

There were seven studies examining the duration of catheter placement at 30 days or less (n = 1286 subjects) and there were three studies examining duration of catheter placement of more than 30 days (n = 6589 subjects). Similar to the aforementioned, NS was equal in efficacy to using HS solution in long-term CVCs (n = 6589; RR, 0.97; 95% CI = 0.76 to 1.23; P = 0.796). By comparison, for short-term study, this analysis demonstrated that NS is less effective than HS (n = 1286; RR, 1.52; 95% CI = 1.02 to 2.27; P = 0.041) (Fig. 6).

Fig. 6.

Fig. 6

Subgroup analysis based on the duration of catheter placement. RR relative risk, CI confidence interval, NS normal saline, HS heparin saline

Discussion

Our systematic review and meta-analysis did not demonstrate a general difference between use of NS or HS in adult populations. In subgroup analysis, stratified by the length of indwelling time (e.g. <30 and >30 days), there appear to be two conflicting conclusions (Fig. 6.) In the short run (<30 days), HS was slightly better than NS. A plausible reason may be that NS has no anticoagulation activity. However, a marginally significant association was observed between using NS vs HS and the incidence of catheter occlusion. Owing to the limited numbers of included studies and the effect sizes, we should treat such a result with caution. By comparison, NS could be equal, if not more effective, in the long run (>30 days). This has implications for patients in whom long-term catheter use may be necessary, for example, in patients undergoing cancer treatment or those requiring dialysis. From a long-term perspective, the use of NS in these patients has several advantages over HS solutions. To begin with, NS is an isotonic solution, which is in accordance with basic physiological needs. In addition, the use of NS will result in fewer side effects from heparin-related complications. Finally, as HS is several times more expensive than NS [32], eliminating its use in flushing solutions has economic benefits.

To date, there have only been three relevant meta-analyses in this area (Additional file 4). The result of the first study (network meta-analysis) was no marked difference, when comparing adult patients with NS vs HS or other solutions in the flushing of CVCs [33]. The second study, consistent with results of previous research, found that HS was not more effective than NS in reducing catheter occlusion when analysed in three different areas (participant, catheter and line access) [18]. These findings challenged the continued use of HS in CVC flushing, as it is more expensive than saline solution. However, a recent study supported NS as a substitution for HS as a locking solution in CVCs in adult patients from the point of view of four different types of CVC [34]. Data from these studies suggests that HS may not be required to maintain the patency of CVCs. In the absence of sufficient evidence to support the use of NS, the debate will be moot. For this reason, further study is needed in this field.

To our knowledge, our study might be the first meta-analysis from the viewpoint of four different CVC-related areas (patient, catheter, lumen and line access) and indwelling time (i.e. <30 and >30 days). Our results, in accordance with current studies, meta-analyses and reviews [18, 27, 33], suggest that there is very little evidence to conclude that flushing with HS has more effect than NS flushing solution for CVC maintenance.

Only a few randomized controlled studies have compared NS with HS for maintenance of CVC lumen patency in adults. The Rabe study was the first RCT to compare the effects of NS versus HS and they determined that the use of a flush containing 5000 U/ml was more effective than NS [13]. In particular, catheter survival rate was higher in the HS group than in NS group. In contrast to the results of the Rabe study, a large number of other studies suggest that the catheter lumen occlusion rate is not different between those with vs those without heparin [10, 2729]. NS flushing for CVCs has been applied in some American ICUs without supporting evidence [35]. Parallel with the mainstream view, Schiffer et al. [17] suggest that routine flushing of CVCs with NS to prevent occlusion is reasonable in this guideline. Morover, a report of a recent multicentre randomized trial [27] argued that HS was not more effective than NS in reducing withdrawal or total occlusion. No statistical difference in catheter patency was observed when comparing NS to HS solution.

Due to the body’s physiologic response to the catheters, nearly 100% of CVCs will develop a “fibrin sheath”, which may increase the risk of catheter occlusion from 1 to 14 days after insertion of the indwelling catheter [36, 37]. As the “fibrin sleeve” usually envelops the tip of the CVC, some argue that a heparin lock could not prevent thrombotic occlusion because of the difficulty in achieving an effective concentration on the outside of the catheter tip [28]. Our findings support these suggestions.

Certainly, the occurrence of CVC occlusion is related to the catheter type, puncture site, heparin concentration, heparin volume, flush frequency, retaining time and the patient’s physical condition [37, 38]. As there are indeterminate factors in this field, further studies, including well-designed trials, are warranted to assess these effects on clinical outcomes.

Various potential limitations should be taken into consideration. First, although the statistical heterogeneity was low, the clinical and methodological heterogeneity cannot be ignored. The latter two types of heterogeneity might be attributed to various types of participants, interventions, outcomes studied (partial or complete occlusion), study designs and study qualities. Second, the potential hazards might occur after long-term follow up, thus, some of these complications could be discarded due to the short duration of some included studies. Third, this meta-analysis was limited to studies conducted in Asia, Europe and North America, and thus, might not be generalizable to other parts of the world. Finally, there was a publication bias in our study as small studies with null results tend not to be published. Hence, uniform study design and multi-centre studies should be launched in different countries and regions to establish the best approach to long-term maintenance of CVCs.

Conclusions

So far, there are still no criteria for flushing and locking techniques, volumes or regimens for safe CVC maintenance. In conclusion, this meta-analysis did not demonstrate any superiority of heparin locked saline solutions over NS for the maintenance of CVC lumen patency in adult patients. Thus, additional large prospective RCTs might be needed in this field due to the inconclusive evidence available.

Key messages

  • Few RCTs have compared NS to HS for prevention of catheter occlusion in adult patients.

  • Pooling the results showed that flushing CVCs with NS is as effective as HS in adult patients, but the 95% confidence interval is wide and spans 1.

  • There is a lack of evidence of the effectiveness of NS flushing compared to HS in keeping CVCs open.

Acknowledgements

We would like to thank all the anonymous reviewers for their valuable comments and suggestions on improving quality of our study.

Funding

This research received no specific grant from any funding agency.

Availability of data and materials

All data are fully available without restriction.

Authors’ contributions

H-ZS and ZL conceived the study idea and designed the study. ZL, YY and WX collected literature, reviewed the articles and collected the data. ZL and W-HL were responsible for the statistical analyses and manuscript. XB, Z-YY, JL and P-ZM helped to draft this manuscript. H-ZS revised it carefully from a professional point of view. All authors have read and approved this final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Abbreviations

CI

confidence interval

CRBSI

catheter-related bloodstream infection

CVCs

central venous catheters

HIT

heparin-induced thrombocytopenia

HS

heparin saline

ICUs

intensive care units

NS

normal saline

PICCs

peripherally-inserted central catheters

RCTs

randomized controlled trials

RR

relative risk

TIVADs

totally implantable venous access devices

Additional files

Additional file 1: (64.5KB, doc)

The PRISMA checklist. (DOC 64 kb)

Additional file 2: (15.8KB, docx)

PICO framework. (DOCX 15 kb)

Additional file 3: (25.6KB, docx)

The search strategy and search results. (DOCX 25 kb)

Additional file 4: (37.5KB, docx)

Characteristics of the three relevant meta-analyses. (DOCX 37 kb)

Contributor Information

Lei Zhong, Email: perfecticu@163.com.

Hai-Li Wang, Email: 1748672427@qq.com.

Bo Xu, Email: 715059718@qq.com.

Yao Yuan, Email: 825150601@qq.com.

Xin Wang, Email: 1169061027@qq.com.

Ying-ying Zhang, Email: 1575593901@qq.com.

Li Ji, Email: 648125668@qq.com.

Zi-mu Pan, Email: 372183414@qq.com.

Zhan-Sheng Hu, Email: icugroup@sina.com.

References

  • 1.Kwakman PH, Muller MC, Binnekade JM, van den Akker JP, de Borgie CA, Schultz MJ, Zaat SA. Medical-grade honey does not reduce skin colonization at central venous catheter-insertion sites of critically ill patients: a randomized controlled trial. Crit Care. 2012;16(5):R214. doi: 10.1186/cc11849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Schallom ME, Prentice D, Sona C, Micek ST, Skrupky LP. Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomized trial. Crit Care Med. 2012;40(6):1820–6. doi: 10.1097/CCM.0b013e31824e11b4. [DOI] [PubMed] [Google Scholar]
  • 3.Bradford NK, Edwards RM, Chan RJ. Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children: A systematic review. Int J Nurs Stud. 2016;59:51–9. doi: 10.1016/j.ijnurstu.2016.02.014. [DOI] [PubMed] [Google Scholar]
  • 4.Smith RN, Nolan JP. Central venous catheters. BMJ. 2013;347:f6570. doi: 10.1136/bmj.f6570. [DOI] [PubMed] [Google Scholar]
  • 5.Mitchell MD, Anderson BJ, Williams K, Umscheid CA. Heparin flushing and other interventions to maintain patency of central venous catheters: a systematic review. J Adv Nurs. 2009;65(10):2007–21. doi: 10.1111/j.1365-2648.2009.05103.x. [DOI] [PubMed] [Google Scholar]
  • 6.Fuentes i Pumarola C, Casademont Mercader R, Colomer Plana M, Cordón Bueno C, Sabench Casellas S, Félez Vidal M, Rodríguez PE. Comparative study of maintenance of patency of triple lumen central venous catheter. Enferm Intensiva. 2007;18(1):25–35. doi: 10.1016/S1130-2399(07)74386-9. [DOI] [PubMed] [Google Scholar]
  • 7.Milani A, Mazzocco K, Gandini S, Pravettoni G, Libutti L, Zencovich C, Sbriglia A, Pari C, Magon G, Saiani L. Incidence and determinants of port occlusions in cancer outpatients: a prospective cohort study. Cancer Nurs. 2016;0(0):1–6. [DOI] [PubMed]
  • 8.van Miert C, Hill R, Jones L. Interventions for restoring patency of occluded central venous catheter lumens (Review) Evid Based Child Health. 2013;8(2):695–749. doi: 10.1002/ebch.1907. [DOI] [PubMed] [Google Scholar]
  • 9.Goossens GA. Flushing and locking of venous catheters: available evidence and evidence deficit. Nurs Res Pract. 2015;2015:985686. doi: 10.1155/2015/985686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Heidari Gorji MA, Rezaei F, Jafari H, Yazdani Cherati J. Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesth Pain Med. 2015;5(2):e22595. doi: 10.5812/aapm.22595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Goode CJ, Titler M, Rakel B, Ones DS, Kleiber C, Small S, Triolo PK. A meta-analysis of effects of heparin flush and saline flush: quality and cost implications. Nurs Res. 1991;40(6):324–30. doi: 10.1097/00006199-199111000-00002. [DOI] [PubMed] [Google Scholar]
  • 12.Goh LJ, Teo HS, Masagoes M. Heparinised saline versus normal saline in maintaining patency of arterial and central venous catheters. In: Proceedings of Singapore Healthcare, vol. 20. 2011. p. 190–6.
  • 13.Rabe C, Gramann T, Sons X, Berna M, González-Carmona MA, Klehr HU, Sauerbruch T, Caselmann WH. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Med. 2002;28:1172–6. doi: 10.1007/s00134-002-1379-2. [DOI] [PubMed] [Google Scholar]
  • 14.Boersma RS, Jie KS, Voogd AC, Hamulyak K, Verbon A, Schouten HC. Concentrated citrate locking in order to reduce the long-term complications of central venous catheters: a randomized controlled trial in patients with hematological malignancies. Support Care Cancer. 2015;23(1):37–45. doi: 10.1007/s00520-014-2320-2. [DOI] [PubMed] [Google Scholar]
  • 15.Buturovic J, Ponikvar R, Kandus A, Boh M, Klinkmann J, Ivanovich P. Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artif Organs. 1998;22(11):945–7. doi: 10.1046/j.1525-1594.1998.06268.x. [DOI] [PubMed] [Google Scholar]
  • 16.Horne MK, McCloskey DJ, Calis K, Wesley R, Childs R, Kasten-Sportes C. Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices. Pharmacotherapy. 2006;26(9):1262–7. doi: 10.1592/phco.26.9.1262. [DOI] [PubMed] [Google Scholar]
  • 17.Schiffer CA, Mangu PB, Wade JC, Camp-Sorrell D, Cope DG, El-Rayes BF, Gorman M, Ligibel J, Mansfield P, Levine M. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(10):1357–70. doi: 10.1200/JCO.2012.45.5733. [DOI] [PubMed] [Google Scholar]
  • 18.López-Briz E, Ruiz Garcia V, Cabello JB, Bort-Marti S, Carbonell Sanchis R, Burls A. Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults. Cochrane Database Syst Rev. 2014;10:CD008462. doi: 10.1002/14651858.CD008462.pub2. [DOI] [PubMed] [Google Scholar]
  • 19.Skinner R, Koller K, McIntosh N, McCarthy A, Pizer B, United Kingdom Children’s Cancer Study G. Paediatric Oncology Nursing Forum Supportive Care G Prevention and management of central venous catheter occlusion and thrombosis in children with cancer. Pediatr Blood Cancer. 2008;50(4):826–30. doi: 10.1002/pbc.21332. [DOI] [PubMed] [Google Scholar]
  • 20.Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Higgins JPT, Green S. Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Chichester, England. Hoboken: Wiley-Blackwell; 2008. [Google Scholar]
  • 22.Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. doi: 10.1136/bmj.327.7414.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111. doi: 10.1002/jrsm.12. [DOI] [PubMed] [Google Scholar]
  • 25.Ge X, Cavallazzi R, Li C, Pan SM, Wang YW, Wang FL. Central venous access sites for the prevention of venous thrombosis, stenosis and infection. Cochrane Database Syst Rev. 2012;3:CD004084. doi: 10.1002/14651858.CD004084.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Goossens GA, Jérôme M, Janssens C, Peetermans WE, Fieuws S, Moons P, Verschakelen J, Peerlinck K, Jacquemin M, Stas M. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Ann Oncol. 2013;24(7):1892–9. doi: 10.1093/annonc/mdt114. [DOI] [PubMed] [Google Scholar]
  • 27.Dal Molin A, Clerico M, Baccini M, Guerretta L, Sartorello B, Rasero L. Normal saline versus heparin solution to lock totally implanted venous access devices: Results from a multicenter randomized trial. Eur J Oncol Nurs. 2015;19(6):638–43. doi: 10.1016/j.ejon.2015.04.001. [DOI] [PubMed] [Google Scholar]
  • 28.Kaneko Y, Iwano M, Yoshida H, Kosuge M, Ito S, Narita I, Gejyo F, Suzuki M. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purif. 2004;22(5):473–9. doi: 10.1159/000081811. [DOI] [PubMed] [Google Scholar]
  • 29.Beigi AA, HadiZadeh MS, Salimi F, Ghaheri H. Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Adv Biomed Res. 2014;3:121. doi: 10.4103/2277-9175.133192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Ziyaeifard M, Alizadehasl A, Aghdaii N, Sadeghi A, Azarfarin R, Masoumi G, Golbargian G. Heparinized and saline solutions in the maintenance of arterial and central venous catheters after cardiac surgery. Anesth Pain Med. 2015;5(4):e28056. doi: 10.5812/aapm28056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Lyons MG, Phalen AG. A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. J Infus Nurs. 2014;37(4):270–81. doi: 10.1097/NAN.0000000000000050. [DOI] [PubMed] [Google Scholar]
  • 32.Bowers L, Speroni KG, Jones L, Atherton M. Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure luer-activated devices. J Infus Nurs. 2008;31(1):22–7. doi: 10.1097/01.NAN.0000308542.90615.c2. [DOI] [PubMed] [Google Scholar]
  • 33.Dal Molin A, Allara E, Montani D, Milani S, Frassati C, Cossu S, Tonella S, Brioschi D, Rasero L. Flushing the central venous catheter: is heparin necessary? J Vasc Access. 2014;15(4):241–8. doi: 10.5301/jva.5000225. [DOI] [PubMed] [Google Scholar]
  • 34.Santos EJ, Nunes MM, Cardoso DF, Apostolo JL, Queiros PJ, Rodrigues MA. Effectiveness of heparin versus 0.9% saline solution in maintaining the permeability of central venous catheters: a systematic review. Rev Esc Enferm USP. 2015;49(6):995–1003. doi: 10.1590/S0080-623420150000600017. [DOI] [PubMed] [Google Scholar]
  • 35.Sona C, Prentice D, Schallom L. National survey of central venous catheter flushing in the intensive care unit. Crit Care Nurse. 2012;32(1):e12–19. doi: 10.4037/ccn2012296. [DOI] [PubMed] [Google Scholar]
  • 36.Yacopetti N. Central venous catheter-related thrombosis: a systematic review. J Infus Nurs. 2008;31(4):241–8. doi: 10.1097/01.NAN.0000326833.59655.9e. [DOI] [PubMed] [Google Scholar]
  • 37.Baskin JL, Reiss U, Wilimas JA, Metzger ML, Ribeiro RC, Pui CH, Howard SC. Thrombolytic therapy for central venous catheter occlusion. Haematologica. 2012;97(5):641–50. doi: 10.3324/haematol.2011.050492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Conway MA, McCollom C, Bannon C. Central venous catheter flushing recommendations: a systematic evidence-based practice review. J Pediatr Oncol Nurs. 2014;31(4):185–90. doi: 10.1177/1043454214532028. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All data are fully available without restriction.


Articles from Critical Care are provided here courtesy of BMC

RESOURCES